These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 8470234

  • 1. Quadruple induction immunosuppression after liver transplantation with interleukin-2 receptor antibody (BT 563) is equally effective and better tolerated than antithymocyte globulin induction therapy.
    Neuhaus P, Bechstein WO, Blumhardt G, Steffen R, Keck H, Lemmens P, Langrehr JM, Schlag H.
    Transplant Proc; 1993 Apr; 25(2):1940-1. PubMed ID: 8470234
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interleukin-2 receptor antibody versus antithymocyte globulin as part of quadruple induction therapy after orthotopic liver transplantation: a randomized study.
    Langrehr JM, Guckelberger O, Nüssler N, Radtke A, Lemmens HP, Jonas S, Lohmann R, Tullius S, Steinmüller T, Raakow R, Neumann U, Knoop M, Bechstein WO, Neuhaus P.
    Transplant Proc; 1996 Dec; 28(6):3204. PubMed ID: 8962241
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antithymocyte globulin or interleukin 2 receptor antibody for immunosuppressive induction therapy after orthotopic liver transplantation: a follow-up study.
    Keck H, Langrehr JM, Knoop M, Lohmann R, Neuhaus P.
    Transplant Proc; 1993 Aug; 25(4):2701. PubMed ID: 8356721
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM, Glanemann M, Guckelberger O, Klupp J, Neumann U, Machens C, Lohmann R, Knoop M, Lobeck H, Schlag H, Keck H, Settmacher U, Bechstein WO, Neuhaus PJ.
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [Abstract] [Full Text] [Related]

  • 8. Incidence and impact of acute rejection episodes on short- and long-term graft survival in recipients of simultaneous pancreas-kidney transplantation.
    Cantarovich D, Giral M, Josien R, Karam G, Hourmant M, Dantal J, Blancho G, Soulillou JP.
    Transplant Proc; 1995 Feb; 27(1):1319. PubMed ID: 7878897
    [No Abstract] [Full Text] [Related]

  • 9. Interleukin-2 receptor antibody vs ATG for induction immunosuppression after liver transplantation: initial results of a prospective randomized trial.
    Lemmens HP, Langrehr JM, Bechstein WO, Blumhardt G, Keck H, Lüsebrink R, Knoop M, Lohmann R, Tullius S, Lobeck H.
    Transplant Proc; 1995 Feb; 27(1):1140-1. PubMed ID: 7878826
    [No Abstract] [Full Text] [Related]

  • 10. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563.
    Langrehr JM, Lohmann R, Raakow R, Jonas S, Klupp J, Bechstein WO, Neuhaus R, Neuhaus P.
    Transplant Proc; 2001 May; 33(3):2290-1. PubMed ID: 11377531
    [No Abstract] [Full Text] [Related]

  • 11. Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation.
    Lohmann R, Langrehr JM, Klupp J, Neumann U, Guckelberger O, Müller AR, Nüssler NC, Jonas S, Lang M, Settmacher U, Bechstein WO, Neuhaus PJ.
    Transplant Proc; 1999 May; 31(1-2):380. PubMed ID: 10083151
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study.
    Oertel M, Sack U, Kohlhaw K, Lehmann I, Emmrich F, Berr F, Hauss J, Schwarz R.
    Transpl Int; 2002 Oct; 15(9-10):463-71. PubMed ID: 12389078
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of OKT3 in kidney, pancreas, and liver transplantation.
    D'Alessandro AM, Pirsch JD, Melzer JS, Sollinger HW, Kalayoglu M, Reed A, Knechtle SJ, Belzer FO.
    Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis.
    Langrehr JM, Lemmens HP, Keck H, Lohmann R, Knoop M, Neumann U, Müller AR, Platz KP, Kling N, Hopf U.
    Transplant Proc; 1995 Feb; 27(1):1215-6. PubMed ID: 7533373
    [No Abstract] [Full Text] [Related]

  • 18. Use of antilymphocyte induction therapy in liver transplantation.
    Wall WJ.
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S64-70. PubMed ID: 10431019
    [Abstract] [Full Text] [Related]

  • 19. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
    van Gelder T, Zietse R, Yzermans JN, Rischen-Vos J, Vaessen LM, Weimar W.
    Transplant Proc; 1996 Dec; 28(6):3221-2. PubMed ID: 8962247
    [No Abstract] [Full Text] [Related]

  • 20. Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation.
    Glanemann M, Langrehr JM, Raakow R, Guckelberger O, Lohmann R, Klupp J, Lobeck H, Schlag H, Keck H, Bechstein WO, Settmacher U, Neuhaus P.
    Transplant Proc; 1998 Aug; 30(5):2159-60. PubMed ID: 9723425
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.